Hepatobilary Flashcards
(155 cards)
Arterial enhancing liver lesions
- HCC
- Haemangioma
- Focal Nodular Hyperplasia
- Hepatic Adenoma
- Primary Hepatic Carcinoid
- METs
- (RCC, Thyropid, NET, Leimyosarc, choricarcinoma, Melanoma, breast, colon, ovarian cystaadenocarcinoma)
Hypervascular liver lesions may be caused by primary liver pathology or metastatic disease.
Differential diagnosis
- Primary lesions
- hepatocellular carcinoma (HCC)
- most common hypervascular primary liver malignancy
- early arterial phase enhancement and then rapid wash out
- rim enhancement of capsule may persist
- haemangioma
- benign;
- most common liver tumour overall
- discontinuous, nodular, peripheral enhancement starting in arterial phase gradual central filling in enhancement must match blood pool in each phase, or not a haemangioma (i.e. similar to aorta in arterial, portal vein in portal phase, etc)
- small haemangiomas (<1.5 cm) may demonstrate “flash filling” - complete homogeneous enhancement in arterial phase (no gradual filling in)
- focal nodular hyperplasia (FNH)
- bright arterial phase enhancement except central scar
- isodense/isointense to liver on portal venous phase
- central scar enhancement on delayed phase
- hepatic adenoma
- arterial phase: transient homogeneous enhancement
- returns to near isodensity on portal venous and delayed phase image
- primary hepatic carcinoid
- background liver disease (cirrhosis)
- vascular shunts
- regenerative nodules
- dysplastic nodules
- hepatocellular carcinoma
- hepatocellular carcinoma (HCC)
What is Budd Chiari syndrome?
What is Budd-Chiari Syndrome?
Budd-Chiari syndrome is a condition in which the hepatic veins (veins that drain the liver) are blocked or narrowed by a clot (mass of blood cells). This blockage causes blood to back up into the liver, and as a result, the liver grows larger. The spleen (an organ located on the upper left side of the abdomen that helps fight infection by filtering the blood) may also grow larger.
Budd-Chiari Syndrome may also cause other conditions, including:
Portal hypertension (increased pressure in the portal vein, which carries blood from the intestines to the liver).
Esophageal varices (twisted veins in the esophagus, or “food tube”).
Ascites (a buildup of fluid in the abdomen).
Cirrhosis (scarring of the liver).
Varicose veins (abnormal, swollen blood vessels) in the abdomen and/or rectum.
What causes Budd-Chiari syndrome?
Budd-Chiari syndrome can be caused by conditions and situations that cause your blood to clot (form a blockage). These include:
Myeloproliferative diseases (those that affect the blood and bone marrow), including polycythemia (the body makes too many red blood cells), and thrombocythemia (the body produces too many platelets).
Sickle cell disease (a blood disease in which red blood cells change shape from round to sickle-shaped).
Inflammatory bowel disease (a group of disorders that cause irritation and swelling of the digestive tract).
Pregnancy.
What are the symptoms of Budd-Chiari syndrome?
The symptoms of Budd-Chiari syndrome include:
Pain in the upper abdomen.
Ascites (swelling in the abdomen caused by excess fluid).
Jaundice (skin, whites of the eyes and mucous membranes turn yellow).
Enlarged and tender liver.
Bleeding in the esophagus.
Edema (swelling) in the legs.
Liver failure.
Hepatic encephalopathy (reduced brain functioning caused by liver disease).
Vomiting.
Enlarged spleen.
Fatigue (extreme tiredness).
can A-1 Anti tryspin deficiency cause cirrhosis?
Alpha-1-antitrypsin deficiency
Assoc Prof Craig Hacking◉◈ and Radswiki◉ et al.
Alpha-1-antitrypsin (A1AT) deficiency is a hereditary metabolic disorder and is the most common genetic cause of emphysema and metabolic liver disease in children. It results in the unopposed action of neutrophil elastase and subsequent severe basal panlobular emphysema and respiratory symptoms. Accumulation of altered alpha-1-antitrypsin in hepatocytes incites an inflammatory response and chronic liver disease.
Epidemiology
Estimated prevalence is thought to be around 1 in 1,500 to 3,500 individuals with European ancestry. It reported to be uncommon in people of Asian descent.
Clinical presentation
The classic presentation of the disease is with dyspnea in the 4th to 5th decades of life. Two-thirds of individuals show clinical features but most carriers are asymptomatic.
Pathology
Alpha-1-antitrypsin (A1AT) is a protein that prevents enzymes such as elastase from degrading normal host tissue. Over 90% of the alpha-1-antitrypsin protein is produced in hepatocytes by codominant gene expression on chromosome 14. The alpha-1-antitrypsin protein inhibits neutrophil elastase. In patients with severe deficiency, the neutrophil elastase acts unopposed resulting in damage to the lower respiratory tract. This damage is predominantly basal because of the gravitational distribution of pulmonary blood flow.
Associations
asthma
pancreatitis
aneurysms, including intracranial aneurysms 18
Radiographic features
Thoracic manifestations
Plain radiograph and CT
panlobular emphysema
the emphysema pattern was traditionally thought to be panlobular, although more recent studies have also suggested a variable pattern to the emphysema
basal predominance, in contradistinction to centrilobular emphysema, which shows apical predominance; the two conditions can coexist in smokers
emphysema may develop in 75-85% of cases 12
bronchiectasis: up to 40% 9
frank bullae formation: non-specific feature 13
bronchial wall thickening: non-specific feature 13
hepatopulmonary syndrome
Nuclear medicine
Reduced perfusion and ventilation in the lower zones on a ventilation/perfusion (V/Q) study.
Abdominal manifestations
Hepatic manifestations of this disease are those of cirrhosis.
Treatment and prognosis
Emphysema and cirrhosis are usually considered the most common causes of death 8.
Survival is substantially worse in smokers, who have a 20-year decrease in longevity relative to non-smokers. According to one study, the overall median survival time was ~55 years 7.
Alpha-1-antitrypsin replacement therapy, most often by weekly intravenous infusions of alpha-1-antitrypsin purified from human plasma, has been used in some situations to partially correct the biochemical defect 14,15.
While randomized, placebo-controlled clinical trials have confirmed a reduction in the decline in lung density in patients receiving augmentation therapy 14, its efficacy in reducing mortality is uncertain 16. Other management strategies include avoidance of smoking and of other risk factors for cirrhosis.
Lung and liver transplant is generally reserved for those with end stage disease 24,25.
Complications
cirrhosis with increased risk of hepatocellular carcinoma 19
A1AT deficiency carriers are at 70-100% increased risk of lung cancer 20
Differential diagnosis
The differential will depend on the organ involved:
for thoracic manifestations: see differential for panlobular emphysema
near identical imaging appearances with ritalin lung
for hepatic manifestations: see differential for cirrhosis
Can Haemachromatosis cause Cirrhosis?
Hemochromatosis
Dr Vikas Shah◉ and Assoc Prof Frank Gaillard◉◈ et al.
Hemochromatosis is an iron overload disorder characterized by a progressive increase in total body iron stores and deposition of iron in some non-reticuloendothelial system (RES) body organs which results in some instances in organ dysfunction.
This article focus on the general principles of hemochromatosis, as well as effects of iron accumulation in the liver, the most frequently affected organ. Clinical and imaging changes in other organ systems are discussed separately:
hemochromatosis: cardiac manifestations
hemochromatosis: skeletal manifestations
hemochromatosis: pancreatic manifestations
hemochromatosis: CNS manifestations
Epidemiology
Hemochromatosis may be primary which is a genetic disorder or secondary which can result from a variety of diseases.
Primary hemochromatosis
Primary hemochromatosis is primarily (90%) due to an abnormal HFE gene, the protein product of which regulates iron absorption from the gastrointestinal tract. The two most common HFE gene mutations are C282Y and H63D. Homozygosity for the C282Y mutation and heterozygosity for C282Y/H63D mutations (also called compound heterozygosity) result in iron overload 7.
Approximately 2-5% of the population are heterozygous carriers (Caucasian population), resulting in a 0.2-0.5% prevalence of homozygous individuals 6. This makes hemochromatosis one of the most common genetic disorders in Caucasians of Northern European ancestry.
Although the genetic defect is distributed equally among men and women, the iron loss as a result of menstruation is protective, resulting in a clinical male predilection (M:F ~ 2:1).
In men, the diagnosis usually becomes evident in middle age (30-40 years of age) whereas, in women, clinical manifestation is delayed until the post-menopausal period.
Secondary hemochromatosis
Secondary hemochromatosis is rare and is usually seen in association with diseases that chiefly cause hemosiderosis. The distribution of iron in both RES and non-RES tissues can thus assist in the imaging differentiation between primary and secondary disease 6.
Etiology
- frequent transfusion
- mainly depositional siderosis in the reticuloendothelial system (RES)
- if > 40 units transfused: then may cause hemochromatosis (non-RES iron deposition)
- high erythrogenic requirements (hemolytic anemia, myelodysplasia)
- mainly depositional siderosis in RES from transfusion
- increased duodenal iron absorption may lead to hemochromatosis (non-RES iron deposition)
- bantau siderosis: rare cause in Africa due to iron-laden locally-brewed beer
Clinical presentation
As hemochromatosis may affect a number of organ systems, patients not surprisingly may present with a variety of signs and symptoms. These are most pronounced in primary hemochromatosis and include 4:
- hyperpigmented skin “bronze”: 90%
- hepatomegaly: 90%
- arthralgia: 50% (see skeletal manifestations of hemochromatosis)
- diabetes: 30% (see pancreatic manifestations of hemochromatosis)
- heart failure/arrhythmia: 15% (see cardiac manifestations of hemochromatosis)
- hypogonadotropic hypogonadism (see CNS manifestations of hemochromatosis)
Pathology
- The fundamental pathology that underlies hemochromatosis is the accumulation of iron and an increase in total body iron stores (as high as 50-60g) and abnormal non-reticuloendothelial deposition, which in turn leads to organ dysfunction.
- Hemochromatosis is distinct from, and should not be confused with, hemosiderosis which refers to the reticuloendothelial system (RES) iron deposition and does not cause organ damage.
- Eventual organ dysfunction is the final step in a cascading sequence of events 5:
- increased gastrointestinal absorption of iron
- increased cellular uptake of iron into non-RES
- liver is the primary organ of deposition
- pancreatic, cardiac, skeletal, and CNS deposition can occur once hepatic deposition is extensive
- iron gets deposited in periportal hepatocytes (ferritin and hemosiderin)
- perilobular fibrosis ensues with fibrous septa
- can progress to cirrhosis with broad fibrous septa surrounding large areas of relatively normal liver parenchyma
Radiographic features
- General visceral features of hemochromatosis are increased organ density (CT) and reduced organ signal intensity (MRI). Secondary imaging features include hepatomegaly, cirrhosis and signs of heart failure.
- The pattern of iron deposition is important. Predominant involvement of the liver, without deposition in spleen or bone marrow, is consistent with non-RES iron deposition and is characteristic of primary hemochromatosis. Iron deposition in the spleen and bone marrow, but to a lesser degree in the liver is consistent with RES deposition and is most likely due to hemosiderosis, which may or may not be associated with secondary hemochromatosis.
CT
- CT, although readily available, is not very sensitive for the diagnosis of hemochromatosis 6. In positive cases, marked homogeneous increase in liver density (75-130 HU) is demonstrated, making the portal vessels and hepatic veins appear of low attenuation relative to the liver on non-contrast CT.
- Dual-energy CT can be used to quantitate iron deposition.
- MRI
- See the sub-article on MRI liver iron quantification.
- MRI is not only the most sensitive imaging modality for the diagnosis of hemochromatosis but is also able to estimate iron concentration within the liver, thus forestalling the need for repeated biopsies 6.
Diagnosis
- Visceral iron results in susceptibility artefact which leads to T2* signal loss. The result is a low signal that is seen on all sequences, but particularly gradient echo and T2. It is useful to compare organ signal to that of skeletal muscle, with lower organ signal than muscle indicating the presence of iron.
- Gradient in-phase and out-of-phase sequences are particularly useful, demonstrating changes that are the opposite of those seen in hepatic steatosis. In hemochromatosis, the liver on in-phase sequence (which is usually obtained second, and thus more susceptible to T2* effects) demonstrates low signal, whereas the out-of-phase sequence demonstrates higher signal 6.
- In primary hemochromatosis, spleen and bone marrow signal is typically normal and low pancreatic signal is usually only seen if there is cirrhosis.
Quantification
- Quantitative MR techniques for measuring iron deposition have been developed, consisting of multiple gradient-echo sequences with progressively increasing TEs. The degree to which signal drops can then be plotted and an estimate of iron concentration generated. In cases with very high concentration, the method is unreliable as too little signal is returned from the liver 6.
- Treatment and prognosis
- Treatment in primary disease involves frequent phlebotomy which improves symptoms such as hepatomegaly, skin pigmentation, lethargy, and abdominal pain. However, arthritis is not affected by therapy. This also improves mild abnormalities of glucose metabolism. However, if type I diabetes mellitus has developed, insulin replacement will still be required. Some improvement in hepatic fibrosis and cardiac dysfunction can also be expected.
- Secondary hemochromatosis and hemosiderosis may require iron chelation therapy, depending on the underlying cause.
- Poor prognostic factors include the development of:
- cirrhosis
- hepatocellular carcinoma (HCC)
- diabetes
- cardiomyopathy
- Differential diagnosis
- General imaging differential considerations for hepatic appearances include:
- hemosiderosis, e.g. thalassemia with iron deposition mainly in spleen/bone marrow compared with primary hemochromatosis where iron is mainly in the liver
- other causes of a hyperdense liver on CT 6
- amiodarone
- Wilson disease
- colloidal gold treatment
can wilsons disease cause cirrhosis?
Wilson disease (hepatobiliary manifestations)
Dr Pablo Lorenzzoni◉ and Dr Yuranga Weerakkody◉ et al.
Hepatobiliary manifestations of Wilson disease vary largely from fatty changes to cirrhosis and occasionally fulminant hepatic necrosis. They result from accumulation of copper in the liver.
For a general discussion of the underlying condition, please refer to the article Wilson disease.
Epidemiology
Hepatic dysfunction is considered the most common manifestation of Wilson disease in childhood, usually presenting at age 10-13 years 5.
Radiographic features
General
The form of liver disease varies, depending on the severity of the disease at the time of diagnosis and pathological findings include fatty changes, acute hepatitis, chronic active hepatitis, cirrhosis and occasionally fulminant hepatic necrosis
The liver can later develop cirrhosis and has several unique radiological findings in comparison to other types of cirrhosis.
Specific features include 1:
multiple nodular lesions in the liver
presence of perihepatic fat layer and normal caudate lobe which is contrary to other types cirrhosis.
CT
Hepatic attenuation can be increased 7 or normal where the latter is thought to result from fatty infiltration and copper deposition canceling effects of each other. Evidence of cirrhosis may be seen in later stages.
Liver MRI
Copper is non-ferromagnetic and therefore cannot be seen on MR imaging.
MR imaging demonstrates the contour abnormalities and parenchymal nodules of the liver in more than half of the patients with Wilson disease, which is thought to correlate with the severity of hepatic dysfunction and clinical manifestations.
commonest finding is cirrhotic change 6
iron in regenerative nodules may result in numerous small nodular T2 hypointensities scattered throughout the liver which can be similar to those of deposits seen in patients with cirrhosis resulting from viral infection
Treatment and prognosis
Medical treatment is usually with copper chelators (D-penicillamine, trientine) or zinc and this can achieve symptomatic improvement and normal life expectancy. Orthotopic liver transplantation is indicated in advanced cases with hepatic decompensation or in patients with fulminant Wilson disease 4.
HCC has been reported in patients with Wilson disease. However, a recent report indicated that the risk of HCC was low in Wilson disease even in cases of cirrhosis8.
References
Can you get HCC in Steatohepatitis without cirrhosis?
yes
Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management
George Cholankeril, Ronak Patel, Sandeep Khurana, and Sanjaya K Satapathy
Author information Article notes Copyright and License information Disclaimer
This article has been cited by other articles in PMC.
Go to:
Abstract
With the prevalence of hepatitis C virus expected to decline, the proportion of hepatocellular carcinoma (HCC) related to non-alcoholic steatohepatitis (NASH) is anticipated to increase exponentially due to the growing epidemic of obesity and diabetes. The annual incidence rate of developing HCC in patients with NASH-related cirrhosis is not clearly understood with rates ranging from 2.6%-12.8%. While multiple new mechanisms have been implicated in the development of HCC in NASH; further prospective long-term studies are needed to validate these findings. Recent evidence has shown a significant proportion of patients with non-alcoholic fatty liver disease and NASH progress to HCC in the absence of cirrhosis. Liver resection and transplantation represent curative therapeutic options in select NASH-related HCC patients but have placed a significant burden to our healthcare resources and utilization. Currently NASH-related HCC is the fastest growing indication for liver transplant in HCC candidates. Increased efforts to implement effective screening and preventative strategies, particularly in non-cirrhotic NASH patients, are needed to reduce the future impact imposed by NASH-related HCC.
Can PBC cause HCC within 10 years?
yes - 4% risk of developing HCC in 10 years. More common in males, older pts, T2DM, and previous HBV.
https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.26176
50% of Cholangioca’s Occur in the CBD.
T/F?
True.
Stat Dx
General Features
Best diagnostic clue
Klatskin tumor: Small hilar mass obstructing bile ducts on CT or ERCP
Location
Distribution in different segments of biliary tree
Distal common bile duct (CBD) (30-50%)
Common hepatic duct (14-37%)
Proximal CBD (15-30%)
Confluence of hepatic ducts (Klatskin tumor) (10-26%)
Isolated left or right hepatic duct (8-13%)
Cystic duct (6%)
Classified based on anatomy and radiographyPeripheral (10%)
Intrahepatic; proximal to secondary biliary radicles
Perihilar (50%)
Klatskin tumor: Hilar tumor involving the confluence of hepatic ducts
Distal (40%)
Extrahepatic; distal CBD
May arise as short stricture or small polypoid mass
Which has the better prognosis?
Intrahepatic vs klatskin tumour?
Intrahepatic 30% 5YS (Dahnert)
Klatskin 11% 5YS (https://www.ncbi.nlm.nih.gov/books/NBK6906/)
Percent of HCC found by USS in screening population?
At best 80% by the best operators in dedicated centres.
But in usual circumstances 65%.

Who are the screening population for HCC?
- Non-cirrhotic HBV
- HCV and Fibrosis
- NAFLD and Fibrosis
- Virtually all cirrhotics
6 monthly.

What is a postive Screening USS for HCC?

What are the Major Criteria for Dx HCC?
- Non- Rim Arterial Phase hyper-enhancement (Non-rim APHE)
- Size >10mm diameter (if less than 10mm -> 3 month screening)
- Enhancing Capsule
- non-peripheral wash out
- Threshold growth

Why can CT/MRI detect HCCs?
- Changes in Blood supply
- angiogenesis
- venous drainage evolution
- other features
- Fibrous capsule/septal formation and other morphological features
- changes in hepatocyte cell membrane transporter function
- increased cellularity (DWI)
why do HCCS have hyper enhancement?
- Marked angiogenesis. Increased unpaired arteries
- Late arterial phase enhancement.
- hall mark of progressed HCC
- not always seen in dysplastic nodules or early HCC.
- Not specific for HCC however.
- You must scan at the right time. Early art phase will not catch the enhancement.
- PIcture 2 is the same patient as picture 1, but done in the early arterial phase ie aortic/angiographic phase. THere hasn’t been enough time for the contrast to get into the lesion.
- Picture 3 shows late arterial phase

Which is most classic for HCC?

Nonrim APHE is. more classical for HCC.
Rim APHE is more classic for Colorectal Mets or intrahepatic Cholangio ca
Rim APHE = LR-M categorization in LI-Rads

What happens to the venous drainage of HCC?
- There are multiple venous changes.
- Change in vascular drainage from hepatic veins to portal veins, therefore predilection for PV invasion
- Rapid drainage of contrast material from lesion
- reduced intralesional portal vein supply
- increased cellularity in lesion, so reduced extracellular volume
- All these findings lead to the phenomenon of WASHOUT in HCC.
- This picture is taken in the LATE VENOUS PHASE (LVP) with the lesion appearing dark cf liver.

What is Wash out?

- here is a lesion showing wash out.
- either in the PV or delayed or late venous phase, the lesion becomes darker than background liver.
- COMPARE this to FADE,
- where the lesion demonstrates arterial phase Hyper Enhancement which then becomes less bright in the PV and Delayed phase,
- but it never gets darker than the adjacent liver.
- Wash out by itself is not specific for HCC.
- Can be seen in
- Cirrhotic/
- regenerative nodules and
- Dysplastic nodules

Is wash out specific for HCC?
Wash out by itself is not specific for HCC.
Can be seen in
- Cirrhotic/
- regenerative nodules and
- Dysplastic nodules
BUT when both of these things happen at the same time:
- Arterial Phase Hyper enhancement
- portal venous phase or late venous phase wash out
Then these features are highly specific for HCC.
- Roughtly 100% specific for HCC > 2cm
- Roughly 90% specific for 1-2cm HCC
Because HCC is supplied by lots of abnormal vessels supplied by hepatic artery branches and altered venous drainage.
If there is sufficient pre-test probability (ie patient with cirrhosis/CLD), with these imaging findings, then we can dx HCC without a liver Bx.

The findings of Non-rim APHE and washout are highly specific for HCC. But how sensitive are they?
- THe findings are unfortunately insensitive.
- up to 40% of small HCCs do not show arterial hyperenhancement
- Approx 50% of small HCCs don’t have typical wash out
- Biopsy still an important tool for lesion with non-diagnostic findings.

What is the ‘capsule’ re HCC?
- Develops as part of hepatocarcinogenesis
- seen in 70% of nodular progressed HCCs
- Not typically seen in cirrhotic nodules, dysplastic nodules or early HCC>

What is a capsule?
- Thin peripheral rim of enhancing tissue in the PV or LVP

What are the typical findings of HCC on CT??

What is Threshold growth RE HCC?
- Size increase of 50% or more in 6 months or less
- one diamter
- only apply if you’re sure its a mass.
- ie don’t apply to a THID or a THAD.
THAD:
Transient hepatic attenuation differences (THAD) lesions refer to areas of parenchymal enhancement visible during the hepatic artery phase on helical CT. They are thought to be a physiological phenomenon caused by the dual hepatic blood supply. Occasionally, they may be associated with hepatic tumours such as hepatocellular carcinoma.
THID:
Transient hepatic intensity differences (THIDs) are a phenomenon observed on MRI imaging of the liver. They are considered a direct equivalent to transient hepatic attenuation differences (THADs) noted on CT. They may be focal or nonfocal.














































































